February 17, 2017
Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial
TheStreet.com
Adam Feuerstein
TheStreet.com
Celgene (CELG) took a step forward toward becoming a major player in the multiple sclerosis treatment market with the announcement Friday of positive results from a late-stage clinical trial of ozanimod. Celgene is conducting a second phase III study of ozanimid in multiple sclerosis patients, with results expected in the second quarter. The positive results from the first phase III study validate Celgene's decision to gain control of ozanimod through the acquisition of Receptos for $7 billion in 2015. Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug responsible for a majority of its revenue and profits.
http://finance.yahoo.com/m/d17775cb-d66a-3840-808c-410cafc307ba/ss_celgene-multiple-sclerosis.html
Gold is $1,581/oz today. When it hits $2,000, it will be up 26.5%. Let's see how long that takes. - De 3/11/2013 - ANSWER: 7 Years, 5 Months